Boston, 13 - 14 April 2027

Schedule

Create your personal agenda –check the favourite icon

Apr 139:10
Conference pass

Making high impact decisions across the value chain to effect access and affordability

Keynotes
Apr 139:30
Conference pass

Advances in Antibodies – the next generation of bispecifics and ADCs

Keynotes
Apr 139:50
Conference pass

The Antibody Landscape: Latest Advances in Novel Multispecific Antibodies and ADCs

Keynotes
Shiva Bhowmik, President + CSO, TRIO Pharmaceuticals, Inc.
Apr 1310:10
Conference pass

Keynote Panel Discussion: AI in Biologics: Progress, Limits, and What Comes Next, sponsored by Cradle

Keynotes
Robert Dillman, Chief Medical Officer, AIVITA Biomedical, Inc.
Apr 1311:00
Conference pass

AI as Copilot, Not Autopilot: The Future of Decision-Making

AI & Data

Artificial intelligence and data analytics are transforming how we work, make decisions, and solve complex problems across industries. Yet, the true potential of AI depends not simply on what algorithms can do, but on how effectively humans prompt, interpret, trust, challenge, and act on their recommendations. This talk explores the evolving partnership between AI and human judgment—where AI can augment expertise, where human intuition remains essential, and why people sometimes override algorithmic recommendations. Ultimately, realizing the promise of AI requires finding the right balance between data-driven intelligence and human expertise to make decisions that are faster, smarter, and more impactful.

Learning Objectives:

  • Recognize when to trust, challenge, or override AI-driven recommendations
  • Understand how AI and human judgment can complement each other in decision-making
  • Apply a balanced human–AI approach to make smarter, faster, and more impactful decisions
Apr 1311:00
Conference pass

Antibody discovery against GPCRs & antibodies as tools for small molecule discovery.

Antibodies for Immunotherapy
Apr 1311:00
Conference pass

Directed Evolution For Engineering Novel Proteins

Protein Engineering
Adrian Hugenmatter, Stanford University
Apr 1311:00
Conference pass

From start-up to scale: cGMP considerations and lessons from a cell therapy hub

Manufacturing
Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Apr 1311:00
Conference pass

New Development of Biosimilars in US, including Immunotherapy agents for cancer, such as pembrolizumab

Biosimilars
Apr 1311:00
Conference pass

Stable cell culture solutions: managing pH and temperature in bioreactors

Bioprocessing
Jean-Francois Hamel, Lecturer, Chemical Engineering, MIT
Apr 1311:20
Conference pass

Title TBA

Manufacturing

Senior Representative Ecolab

Apr 1311:20
Conference pass

Title TBA

Antibodies for Immunotherapy

Senior Representative, Sartorius

Apr 1311:20
Conference pass

Title TBA

Bioprocessing

Senior Representative, Catalent

Apr 1311:40
Conference pass

Building a Manufacturing Process in Low Earth Orbit — Infrastructure, Supply Chain and Regulatory Pathways

Manufacturing

Microgravity is usually discussed as a research environment. Eascra is treating it as a manufacturing parameter. Janus Base Nanoparticles — a DNA-inspired, non-lipid delivery platform designed to reach tissue types lipid nanoparticles cannot reliably access — show measurably better structural consistency and therapeutic performance when formulated in orbit than in matched Earth-made controls. Turning that observation into a supply chain is a different problem from proving it.

Under NASA's InSPA Phase II contract, Eascra is developing semi-autonomous production hardware with two independent engineering partners, running coordinated synthesis campaigns aboard the ISS, and returning material for ground characterisation. This session covers what industrialising that actually requires: the hardware and infrastructure needed for autonomous production off-planet, the reagent stability and cold-chain constraints that shape an orbital supply chain, and the regulatory work of framing microgravity as a controllable process parameter under ICH Q8, Q9 and Q10 rather than an exception to them.

  • Why microgravity changes the product rather than just the experiment — comparative data on JBNp structural consistency, cargo loading and delivery efficiency against Earth-made controls
  • What orbital manufacturing infrastructure demands in practice — semi-autonomous production hardware, remotely triggered synthesis runs, reagent stability windows, and downmass and cold-chain design
  • Building a regulatory pathway that mirrors terrestrial standards — treating microgravity as a controllable GMP process parameter under ICH Q8/Q9/Q10, and what that implies for scale-up and eventual commercial supply
Apr 1311:40
Conference pass

Development of OR502, in antibody against leukocyte immunoglobulin-like receptor B2, to overcome suppression in the tumor microenvironment

Antibodies for Immunotherapy
Kamal Puri, CSO, OncoResponse
Apr 1311:40
Conference pass

Formulation development for biologics

Bioprocessing
Kanika Sarpal, Principal Scientist, Sanofi
Apr 1311:40
Conference pass

Launching a biosimilar: the US landscape for biosimilar products

Biosimilars
Christina Hartman, Head of Government Affairs and Washington, DC Office, Orchard Therapeutics
Apr 1311:40
Conference pass

Predictive frameworks to improve drug discovery

AI & Data
Yu Tian, Director II, Abbvie
Apr 1311:40
Conference pass

Structural biology approaches to protein engineering

Protein Engineering
Dirk Zajonc, VP, Protein Engineering, Mirador Therapeutics
Apr 1312:00
Conference pass

Applying AI to the engineering novel antibody therapies

AI & Data
Michael Peer, Director of Computational Biology, Biolojic Design
Apr 1312:00
Conference pass

Cancer immunotherapy using bispecific gamma delta T cell engagers

Antibodies for Immunotherapy
Hans van der Vliet, Medical Oncologist, Amsterdam UMC
Apr 1312:00
Conference pass

Continuous downstream processing advances

Bioprocessing
Vishwanath Hebbi, Senior Scientist, Merck
Apr 1312:00
Conference pass

Revolutionizing Cancer Care: the impact of biosimilars on the Community Oncology Frontline

Biosimilars
Melody Chang, VP of Pharmacy Operations, American oncology network
Apr 1312:00
Conference pass

Title TBA

Protein Engineering
Kenta Shinoda, Principal Scientist, Pfizer
Apr 1312:00
Conference pass

Title TBA

Manufacturing
Steven Feldman, Site Head and Scientific Director, Stanford GMP Facility, Stanford School of Medicine/Stanford HealthCare
Apr 1312:45
Conference pass

No one builds alone - How to create the best community, support systems, and teams

Innovation
  • Cultivating your community.Building your network isn't something you should only do when times are tough. It's a foundation you need to build before you need it. And finding the right communities and networks can make all the difference.
  • Lean on your support system. Let people in earlier than you'd like, and lean on them for support along every step of the journey.
  • Be patient and thoughtful when building your team. It's better to hire right rather than hire fast. The wrong early teammate could cost you more than the empty seat did.
Apr 1313:05
Conference pass

The Science of Talent in Biopharma – Measuring Human Performance as a Strategic Asset

Innovation
    Biopharma 4.0 transforms discovery, clinical, and manufacturing systems, workforce capability has emerged as a strategic differentiator. This session explores how predictive, finance-grade talent analytics can measure and optimise human performance, linking Talent Efficiency (TE) directly to productivity, quality, and financial outcomes.

    Key Takeaways:

  • Introduces a quantitative Talent Efficiency framework applied by leading CDMOs, ATMP developers, and biologics manufacturers.
  • Demonstrates how data-driven models quantify workforce readiness and return on capability investment.
  • Provides a European benchmarking perspective on skills gaps, digital maturity, and the next-generation biomanufacturing workforce.

    I’ve delivered Talent Science™ Boardrooms and keynotes at major global conferences including BPI (Europe & Boston), The Economist, Advanced Therapies, Bio-IT, Bio-Europe and DCAT, and would be delighted to explore how this could enhance the Festival’s strategic and leadership-focused sessions.

Jason Beckwith, Professor, BioTalent
Apr 1313:25
Conference pass

Hiring Smarter Starts Earlier: How Educational Programs Can Close the Cell and Gene Therapy Workforce Gap

Innovation
  • The problem: CGT pipeline and funding growth are outpacing workforce development, with the longest hiring delays in QC, analytical development and manufacturing.
  • A model that works: Industry-informed curriculum, hands-on training, flexible delivery, and a structured co-op that lowers hiring risk and cost for employers.
  • How to engage: Join an advisory board, host a co-op or directed study, tell programs where the curriculum is behind, and hire graduates.

Apr 1313:50
Conference pass
Apr 1313:50
Conference pass

Biophysical characterisation and analytics of novel proteins

Manufacturing
David Boggs, Senior Scientist I - Protein Analytical Characterization Biotherapeutics and Genetic Medicine, Research and Discovery, Abbvie
Apr 1313:50
Conference pass

Bioprocessing to make biosimilars accessible

Biosimilars
Julio Baez, Bioengineering Industrial Advisor, University of California San Diego
Apr 1313:50
Conference pass

Engineering protein scaffolds for novel bispecific antibodies

Protein Engineering
Apr 1313:50
Conference pass

Maximizing the power of bispecific therapies for treating solid tumors

Antibodies for Immunotherapy
Apr 1313:50
Conference pass

Vector construction for protein expression

Bioprocessing
Ilya Tikh, Sr. Principal Scientist, Pfizer
Apr 1314:10
Conference pass

Title TBA

Manufacturing

Senior Representative, FUJIFILM

Apr 1314:10
Conference pass

Title TBA

Protein Engineering

Senior Representative KACTUS

Apr 1314:10
Conference pass

Title TBA

Bioprocessing

Senior Representative, Weave Bio

Apr 1314:10
Conference pass

Title TBA

Biosimilars

Senior Representative, SCIEX

Apr 1314:30
Conference pass

Ensuring High Biosimilarity Through Advanced Processes and Characterization Approaches

Biosimilars
Sanjeev Gupta, Sr. Vice President and Head -Biosimilar (R&D, Mfg. and BD), Ipca Laboratories Ltd
Apr 1314:30
Conference pass

Improved data generation for ML models using Continuous Directed Evolution Sequences

AI & Data
Anshika Gupta, Project Scientist, UCI
Apr 1314:30
Conference pass

Polysaccharide drug substance production: Optimization and scale-up of purification unit operations

Bioprocessing
Sidharth Razdan, Principal Scientist, Pfizer
Apr 1314:30
Conference pass

Real-Time and Label-Free Binding Kinetics of Membrane Protein-Ligand Interactions in a Membraneless and High-Throughput Setting

Protein Engineering
Liviu Movileanu, Professor, Department Of Physics, Syracuse University
Apr 1314:30
Conference pass

Title TBA

Antibodies for Immunotherapy
Daniela Cipolletta, Senior Director of Immunology, Seismic Therapeutic
Apr 1314:30
Conference pass
Apr 1314:50
Conference pass

Cell‑Free Antibody Engineering: Accelerating Discovery and Screening with PUREfrex®

AI & Data

PUREfrex® is a fully reconstituted, cell‑free protein expression system enabling rapid, high‑throughput antibody engineering. It efficiently produces scFv, Fab, and IgG, and supports robust ribosome display (PUREfrexRD) for screening highly diverse libraries. Combined with AI/ML workflows, PUREfrex® accelerates discovery of next‑generation antibodies and cyclic peptide modalities with enhanced precision, flexibility, and scalability for biologics R&D.

Apr 1314:50
Conference pass

Title TBA

Bioprocessing

Senior Representative, Lonza

Apr 1315:10
Conference pass

Analytical development and characterization of biosimilars

Biosimilars
Parastoo Azadi, Technical Director Of Analytical Services And Senior Research Scientist, Complex Carbohydrate Research Center
Apr 1315:10
Conference pass

Automating Mid-scale Antibody Production: Bridging the Gap in Discovery Workflows with Novel Liquid Handling and Filtration Technologies

Protein Engineering
Ayla Sessions, Associate Director, High-Throughput Production, AstraZeneca
Apr 1315:10
Conference pass

Engineering challenges in manufacturing ADCs

Manufacturing
Savita Bhutoria, Senior Scientist, Gilead
Apr 1315:10
Conference pass

Exploring costimulatory receptors CD28 and 4-1BB for cancer immunotherapy

Antibodies for Immunotherapy
Changchun Du, Senior Principal Scientific Researcher, Genentech
Apr 1315:10
Conference pass

Process characterization and purification of proteins

Bioprocessing
Olga Sharapova, Senior Principal Scientist, Pfizer
Apr 1315:10
Conference pass

The Deliverome Project: Mapping Surface Protein Abundance and Internalization for Precision Delivery

AI & Data

Deliverome Bio is a nonprofit research organization mapping surface protein abundance and internalization across the human surfaceome to identify new targets for precision delivery of biologic therapeutics. Doing so first requires a reliable list of surface proteins, yet the five most widely used databases collectively identify 5,546 proteins and agree on only 188. We developed an agentic LLM pipeline that classifies candidates using full-text scientific literature, yielding an open, evidence-linked atlas of the accessible human surfaceome that includes 1,108 candidates absent from all five databases. The atlas and its underlying literature evidence are publicly accessible through our interactive viewer (surfaceome.deliverome.org) and API. We are building on this resource with systematic ORF-based screens of surface protein abundance and internalization, alongside surface proteomics in primary cells and tissues, to enable data-driven discovery and prioritization of receptors for precision delivery.

Apr 1315:30
Conference pass

Panel Discussion: Finance & Investment

Finance & Investment
Moderator: Jae Sly, CEO, Pathways Preclinical Partners
Apr 1315:30
Conference pass

The Patient Experience: Considering the Clinic and Beyond

Clinical Trials
Petra Duran, Director of Patient Experience, ImYoo Health
Apr 1315:50
Conference pass

The Evolving Regulatory Landscape of Clinical Trials

Clinical Trials
Kim Walker, Faculty Director & Graduate Advisor Center for Regulatory Science, San Diego State University
Apr 1316:10
Conference pass

Ensuring Quality Control in Clinical Trials

Clinical Trials
Cheryl Marcotte, Sr Director, GSK
Apr 1316:40
Conference pass

Engineered cytokine/antibody fusion proteins as novel drugs for cancer immunotherapy

Protein Engineering
Jakub Tomala, Assistant Research Professor, John Hopkins University
Apr 1316:40
Conference pass

Engineering a novel mAb based contraceptive

mAbs
Keiichiro Kushiro, Senior Director of Research, Mucommune
Apr 1316:40
Conference pass

Examining novel cell expression platforms

Bioprocessing
Nimi Vashi, Co-Founder & CEO, Buzz Biolabs
Apr 1316:40
Conference pass

Leveraging AI in Computational Medicine

AI & Data
Wei Wang, Professor, University of California San Diego
Apr 1316:40
Conference pass

Stability controls for high concentration formulations

Manufacturing
Samiul Amin, Professor of Practice, Chemical Environmental and Materials Engineering and Director, University of Miami
Apr 1316:40
Conference pass

Streamlined Development: 2-year perspective what's changed

Biosimilars
  • Biologic expiration in the next 10 years is >100 but there is a biosimilar void due to the high cost of development
  • WW health authorities have recognized the advancements in analytical comparability is a more precise tool than a CES trial to detect difference between RLD and a proposed biosimilar
  • CES trial is a blunt endpoint (there must be large differences between a proposed biosimilar and a reference to detect differences in an efficacy trial)
  • HA have changed guidance's to allow for an application without the comparative efficacy trial saving companies significant time and money in their development
  • however, there are implications asnow there is an intense focus on analytical and functional comparability
Apr 1317:00
Conference pass

Title TBA

Protein Engineering

Senior Representative, Nuclera

Apr 1317:00
Conference pass

Title TBA

Manufacturing

Senior Representative, SGS

Apr 1317:20
Conference pass

A Roadmap for Actionable AI usage

AI & Data
Stephan Krause, Executive Director, Analytical Strategy, Bristol Myers Squibb
Apr 1317:20
Conference pass

Hybrid modality engineering

Protein Engineering
Sunny Zhou, Professor, Northeastern University
Apr 1317:20
Conference pass

PANEL DISCUSSION: Scaling the Frontier: Key Logistics, Supply Chain, and Commercialisation Strategies in Cell Therapy Manufacturing

Manufacturing

· Regulatory Adaptation & Global Logistics

· Supply Chain & Node Resilience

· Transitioning & Scaling Operations

  • The Evolution of Hub-and-Spoke Models
Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Kinkini Roy, Director, Mohican Tx
Apr 1317:20
Conference pass

Predicting the Regulators: How AI is Revolutionizing Biosimilar Development and Approval Strategy

Biosimilars
CHANDRIKA SAMIR PATEL, Vice President - Global Regulatory Affairs, Kashiv BioSciences LLC.
Apr 1317:20
Conference pass

The Immune Epitope and Cancer Epitopes Databases as Tools to Support Development and Testing of Biologics

mAbs
Apr 1317:20
Conference pass

The importance of talent: supporting the bioprocessing operations of tomorrow with the right people

Bioprocessing
Greg Hammond, Head of Technical Operations, BioTalent
Apr 1317:40
Conference pass

An AI driven, cell-free vaccine platform

AI & Data
Prasun Chakraborty, Founder & CEO, Genevation LTD
Apr 1317:40
Conference pass

Downstream operations for protein purification

Protein Engineering
Richard Martel, Operations Director, Bristol Myers Squibb
Apr 1317:40
Conference pass

Enhanced Antibody Effector Function Through Glycoengineering

mAbs
Qiang Chen, Professor, Biodesign Institute at Arizona State University
Apr 1317:40
Conference pass

What the Biology Can't Fix: Good science doesn't automatically become good medicine. Some things have to be right before the biology even gets its chance

Biosimilars
David Maasz, Chairman, BioFund Family Office

Create your personal agenda –check the favourite icon

Apr 149:45
Conference pass

Plenary Panel: Beyond the Atmosphere: Unlocking Space and Microgravity for Biologics Manufacturing and Commercialisation, sponsored by BioOrbit

Keynotes
Ken Savin, Chief Scientific Officer, BioOrbit
Nicole Wagner, CEO, LambdaVision, Inc.
Moderator: Scott Robinson, CSO, MicroQuin
Apr 1411:00
Conference pass

Title TBA

Protein Engineering

Senior Representative, ChemPartner

Apr 1411:00
Conference pass

Title TBA

CMC

Senior Representative,Minaris Advanced Therapies

Apr 1411:20
Conference pass
Apr 1411:20
Conference pass

Advancing AI for Drug Discovery

AI & Data
Hans Bitter, Head of Computational Science & Data Strategy, Research, Takeda
Apr 1411:20
Conference pass

Beginning with the End in Mind: Using the Target Product Profile to Guide Biologics Drug Product Development

CMC
Apr 1411:20
Conference pass

Developing New Cancer Immunotherapies: From Bark to Bedside

Advanced Therapies
Mark Mamula, Professor Of Medicine Rheumatology, Yale University
Apr 1411:20
Conference pass

PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 Glycans in Solid Tumors

Armed Antibodies
Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc
Apr 1411:20
Conference pass

Trispecific antibody engineering: protein engineering fundamentals

Protein Engineering
Genevieve Desjardins, Associate Director in Protein Engineering, Zymeworks Inc
Apr 1411:40
Conference pass

A Novel CTPS1 Inhibition Approach

Oncology
Apr 1411:40
Conference pass

Approaches to developing cell based bioassays

CMC
Hanief Shahjee, Associate Director, Teva Pharmaceuticals
Apr 1411:40
Conference pass

From Hours to Minutes: Rapid Protein Measurement for Bioprocess Development and Manufacturing

Protein Engineering

Biologics development and manufacturing require the measurement of proteins throughout the process—from monitoring critical process parameters and product quality attributes to detecting impurities and contaminants. However, many protein measurements still rely on laboratory-based assays that take hours or longer to return results, require skilled technicians, and involve multiple reagent addition and washing steps. As a result, important protein measurements are often performed only at selected points in development or as end-point quality tests rather than being used to guide processes in near real time.

Rapid, protein-specific measurements could provide valuable information during both process development and manufacturing. During development, faster measurements could allow scientists to evaluate process changes more quickly and better understand how these changes affect the product. During manufacturing, at-line protein measurements could identify process deviations earlier, potentially reducing lost batches, manufacturing delays, and costs while enabling greater process control and automation. Host cell proteins (HCPs) provide an important example. HCPs can co-purify with a therapeutic protein, and some may affect product stability, efficacy, or patient safety.

Advanced Silicon Group (ASG) is developing NanoSwift™, a silicon-based, label-free electrical biosensor platform designed for rapid, quantitative protein measurements. The technology is intended to measure specific proteins in less than 15 minutes with minimal hands-on time and low sample volume. Because NanoSwift generates an electrical signal and can be multiplexed to measure multiple proteins, it has the potential to support automated, at-line measurements during biologics development and manufacturing.

This presentation will discuss the opportunities created by moving protein measurements closer to the bioprocess, including applications in process development, process monitoring, product characterization, and impurity detection. High-risk HCP measurement will be presented as one example of how rapid, protein-specific measurements could provide information that is difficult to obtain with current methods. Ultimately, faster access to protein data could help biopharmaceutical manufacturers develop processes more efficiently, identify problems earlier, improve process control, and manufacture biologics more consistently.

Apr 1411:40
Conference pass

hase 1 Study of Micvotabart Pelidotin (MICVO) Monotherapy in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Armed Antibodies
Hongwei Wang, SVP, Head of ADC Development & Clinical Strategy, Pyxis Oncology
Apr 1411:40
Conference pass

Next Generation CAR-T for liquid tumours and autoimmune diseases

Advanced Therapies
Elena Gonzalez, Director of CMC, GenCART Bio
Apr 1411:40
Conference pass

Using AI ML to make Biobetters

AI & Data
Christopher Negron, Research Scientist, AbbVie
Apr 1413:20
Conference pass

Advances in antibody-radioconjugate technology

Armed Antibodies
Fariba Khanshan, Director Radioconjugate PK/PD/PMX, AstraZeneca
Apr 1413:20
Conference pass

An autologous platform for production of novel Cell and Immunotherapies

Advanced Therapies
Robert Dillman, Chief Medical Officer, AIVITA Biomedical, Inc.
Apr 1413:20
Conference pass

Analytical development of novel antibodies

CMC
Chris Chumsae, Director of Biophysical-Chemical Characterization, Bristol Myers Squibb
Apr 1413:20
Conference pass

Characterization of T Cell Engaging Bispecific Antibodies and Combination Therapies with a High-Throughput Multiparametric Automated Assay and Data Analysis Platform

Protein Engineering
Apr 1413:20
Conference pass

Next generation mAbs: new frontiers in cancer treatment

Oncology
Apr 1413:20
Conference pass

Syntein™ Platform: AI-Designed D-Amino Acid Proteins as a New Class of Supranatural Protein Therapeutics

AI & Data

Conventional biologics are constrained by their reliance on the 20 naturally occurring L-amino acids, limiting achievable pharmacological properties such as protease resistance, immune evasion, and tissue penetration. D-amino acid proteins have long been recognized as intrinsically resistant to proteolytic degradation and immune recognition, but their therapeutic utility has been constrained by the inability to rationally design D-proteins capable of engaging natural biological targets.

We developed a fully integrated, digital and automated platform combining generative AI-based de novo protein design with chemical synthesis to generate "Synteins™"—programmable protein therapeutics built from an expanded set of synthetic building blocks, including D-amino acids. The platform applies folding principles derived from natural proteins to design D-protein binders, inhibitors, agonists, and delivery vehicles de novo against virtually any therapeutic target, circumventing the cell-based production constraints of conventional biologics.

Using this platform, we report the first experimentally confirmed structure of a de novo, AI-designed, all-D-amino-acid protein bound to a natural biological target. This result demonstrates that computationally designed D-proteins can achieve specific, structurally validated engagement with natural targets despite their non-natural chirality. Synteins generated through this approach retain compatibility with human biology while exhibiting enhanced resistance to protease-mediated degradation and reduced immune recognition relative to conventional L-protein biologics.

This work establishes a generalizable platform for designing D- protein therapeutics with tunable pharmacological properties, including extended durability, immune stealth, and expanded tissue access (e.g., brain, kidney, liver, tumor). These findings support the feasibility of SynteinsTM as a new therapeutic modality with potential applications across oncology, immunology, and metabolic disease, and highlight a path toward less frequent dosing and oral delivery of protein-based medicines.

Apr 1413:40
Conference pass

Multi-Objective Optimization for Antibody Design Under Uncertainty

AI & Data
  • In this talk, a computational method is presented that jointly optimizes binding affinity and developability properties in antibody design.
  • The framework integrates multiple predictive oracles trained on multi-modal data spanning diverse data types, experimental platforms, and levels of fidelity.
  • By explicitly modeling uncertainty, the method guides selection of high-affinity, low-risk candidates despite noisy or conflicting predictions, enabling confident multi-objective decisions in biologics discovery.
Rizki Mardian, Principal Scientist, GSK
Apr 1413:40
Conference pass

The promises and challenges of IPS-derived cell therapies

Advanced Therapies
Apr 1414:00
Conference pass

Developing T cell Engagers Against novel pHLA Targets

Oncology
Apr 1414:00
Conference pass

From Discovery to Market: U.S. Leadership in Gene Therapy Innovation

Advanced Therapies
Enrique Seoane-Vazquez, Professor of Pharmaceutical Economics, Regulation and Policy, Chapman University
Apr 1414:00
Conference pass

Integration of Survival Analysis and Workflow Assistant on a Hybrid Interactive Machine Learning Tool for Whole Slide Image Analysis

AI & Data

Our team has been developing an interactive machine learning software tool, named Hybrid Interactive Machine Learning Tool to assist physicians in quickly and accurately identifying regions of interest in WSIs by adopting state-of-the-art artificial intelligence algorithms.Integratingsurvival prediction and a conversational AI assistant into HIMLT will make it more clinically useful by helping doctors not just find tumors but understand patient outcomes and use the software more easily. In this presentation, we will talk about how we integrate two modules into the software tool and what to expect fromtheir results.

Sanghoon Lee, Associate Professor of Computer Science, Kennesaw State University
Apr 1414:00
Conference pass

Protein generation to support exploratory immunology

Protein Engineering
Andrew DiChiara, Senior Scientist II, Abbvie
Apr 1414:00
Conference pass

Radiopharmaceuticals for oncology

Armed Antibodies
Riccardo Canevari, CEO, Radiopharm Theranostics
Apr 1414:00
Conference pass

Stability support for early clinical programs

CMC
Jun Zhang, Associate Director, Amgen Inc
Apr 1414:20
Conference pass

Advances in high throughput screening technologies for antibody production

Protein Engineering
Christopher Wassif, Senior Director-Emerging Technologies & High-Throughput Platforms, AstraZeneca
Apr 1414:20
Conference pass

Applications of AI/ML in Packaging Development for Biosimilar Products

AI & Data
Apr 1414:20
Conference pass

Novel Gene Therapies for Rare Diseases

Advanced Therapies
Mat Pletcher, CSO, Arbor Biotechnologies
Apr 1414:20
Conference pass

Novel ligan-based bispecific drug conjugates targeting prostate cancer

Oncology
Apr 1414:20
Conference pass

Precision Bioconjugation to Build Next-Generation Biotherapeutics

Armed Antibodies
  • Site-specific incorporation of bioorthogonal noncanonical amino acids into proteins enables their subsequent chemical modification with unprecedented versatility and precision
  • This approach allows generation of diverse, homogeneous conjugates from the same starting components by systematically varying the site and stoichiometry of labeling
  • Conjugate variants built from identical components display diverse physicochemical and pharmacological properties — an underutilized lever for fine-tuning biologics
  • The technology further enables construction of macromolecular conjugates not readily accessible by conventional means, unlocking a new class of next-generation therapeutics
Abhishek Chatterjee, Professor of Chemistry, Boston college
Apr 1414:20
Conference pass

Selecting biologic candidates to accelerate development and reduce costs

CMC
Kamal Egodage, Founder and President, Lasanth Consulting
Apr 1414:40
Conference pass

Advancing novel cancer treating antibody therapies, powered by AI

Oncology
Jan Schnitzer, Director, P.R.I.S.M.
Apr 1414:40
Conference pass

De novo designs for recombinant antibodies

Protein Engineering
Lindsay Hammack, Associate Principal Scientist, Merck
Apr 1414:40
Conference pass

From Propagation to Push-Button: Ready-to-Use Cells and Robotic Liquid Handling in Bioassay QC Lab

CMC

Bioassays are central to release, stability, and comparability testing of biologics, and must deliver robust, precise results across both GMP and development laboratories. Routine workflows, however, depend on multi-day cell passaging and manual pipetting, thereby introducing cell lot-to-lot and operator-to-operator variability, ergonomic strain, and a heavy documentation burden. This talk presents two complementary strategies for building a leaner, more reliable bioassay operation. Ready-to-use cells replace in-house propagation with a single freeze-thaw step and offer a more consistent starting point, with reduced contamination risk and simpler logistics across sites. Automated liquid handling on Hamilton platforms takes over repetitive, high-precision steps like dilutions and reagent addition, adds consistency, reduces analyst-to-analyst variability, and frees scientists from repetitive manual pipetting. Together, these approaches address both the biological and mechanical sources of bioassay variability, drawing on practical experience implementing both in a regulated environment.

Maroun Beyrouthy, Senior Advisor, Eli Lilly
Apr 1414:40
Conference pass

Gene Therapy for Cancer and Inflammatory Diseases

Advanced Therapies
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Apr 1414:40
Conference pass

Managing Clinical Data Effectively and Securely

AI & Data
Mats Sundgren, Senior Industry Scientific Director, i-hd (The European Institute for Innovation through Health Data)
Apr 1414:40
Conference pass

Unnatural Precision: Site-specific conjugation for next generation ADCs

Armed Antibodies
  • Impact of Design: Conjugation site and chemistry heavily dictate the functional properties of antibody-drug conjugates (ADCs).
  • Next-Gen Stability: Replacing unstable thiol-maleimide chemistry and exposed conjugation sites yields novel ADCs with superior therapeutic indices.
  • Multi-Payload Potential: Combining distinct, complementary chemistries enables the precise production of dual-payload ADCs.
Apr 1415:00
Conference pass

Accelerating mRNA Purification Process Development Through Mechanistic Modeling of Oligo-dT Chromatography

CMC

OligodeoxyThymidine (Oligo-dT) affinity chromatography can be used for mRNA purification, exploiting poly-A tail binding to remove impurities. However, process variability and construct-size-dependent behavior challenge yield optimization and GMP consistency. Mechanistic modeling offers data-driven approach to these challenges and accelerate process understanding.

Model calibration achieved R²≥0.95 for UV fit, with <1% parameter error for the target mRNA and <5% for fragments across experiments. Three optimization strategies were evaluated using the calibrated model: (1) Wash Strategy: in silico simulations of GMP wash step matched experimental data, validating predictive fidelity; (2) Dynamic Binding Capacity (DBC) Strategy: simulations revealed steric exclusion of larger constructs from internal pores, with increased load residence time significantly improving binding; (3) Buffer Optimization: screening identified elution conditions that reduced variability and improving pH stability. Model-guided optimization enabled mechanistic understanding of the process, reducing empirical experimentation for wash step evaluation, DBC enhancement, and buffer optimization. This framework accelerates process development, improves product quality, and supports platform-level mRNA manufacturing decisions.

This work was previously presented at the 5th mRNA Process Development & CMC Summit 2026 held in Boston (MA), Sep 30- Oct 1, 2026.

This work was funded by Sanofi.

All authors are or were Sanofi employees and may hold shares or stock options in the company.

Apr 1415:00
Conference pass

Developing a chimeric antigen receptor tumor cell therapy (car-tumor

Advanced Therapies
George Zhou, Founder & CEO, Joint Biosciences
Apr 1415:00
Conference pass

Engineering Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy

Armed Antibodies

Antibody–drug conjugates (ADCs) are powerful targeted therapies but are limited by narrow payload diversity and chemical constraints. In this talk, I will introduce antibody–bottlebrush prodrug conjugates (ABCs) that overcome these barriers. ABCs feature antibodies covalently linked to polymeric bottlebrush prodrugs carrying diverse, tunable payloads at ultra-high drug-to-antibody ratios. This design enables precise tumor targeting, superior efficacy, and minimal toxicity in preclinical models, offering a promising next-generation therapeutic strategy.

Apr 1415:00
Conference pass

Engineering Next-Generation T-Cell Engagers for Solid Tumors

Protein Engineering

·Developed a multispecific TCE platform integrating tumor targeting, T-cell engagement, and costimulation.

·Optimized TCEs enhanced T-cell activation, persistence, and tumor cell killing in preclinical studies.

·Integrated costimulation may improve the potency and durability of TCEs for solid tumors

Apr 1415:00
Conference pass

Pathomics tools to Map and Quantify TILs in Cancer for Precision Oncology

AI & Data
Apr 1415:40
Conference pass

Panel Discussion: Beyond the Hype: AI's Real Impact on Biologics Development

AI & Data

· Where AI genuinely accelerates discovery and development vs. overpromised applications

· Data quality, integration, and governance challenges across the biologics pipeline

· Regulatory perspectives on AI-driven decision-making in drug developmen

Apr 1415:40
Conference pass

Panel Discussion: From Bench to Bedside: Overcoming CGT Commercialization Hurdles

Advanced Therapies
Apr 1415:40
Conference pass

Panel Discussion: Payload Precision: Next-Generation ADCs and Beyond

Armed Antibodies
  • Optimizing linker-payload chemistry for improved therapeutic index and reduced off-target toxicity
  • Novel conjugation platforms: site-specific vs. stochastic approaches and their impact on manufacturability
  • Lessons from recent clinical failures and successes in antibody-drug conjugate development
Apr 1415:40
Conference pass

Panel Discussion: Scaling Smart: De-Risking Biologics CMC and Supply Chains

CMC

· Single-use vs. stainless steel: capacity planning for unpredictable clinical demand

· Continuous manufacturing and process intensification—readiness for widespread adoption

· Building supply chain resilience post-pandemic: lessons learned and future-proofing strategies

Apr 1415:40
Conference pass

Panel Discussion: The Next Wave of Oncology Biologics: Combination Strategies and Resistance

Oncology
  • Rational design of combination approaches (bispecifics, ADCs, immunotherapies) to overcome resistance
  • Biomarker strategies for patient stratification in an increasingly crowded pipeline
  • Translating solid tumor microenvironment insights into more effective biologic therapies
Ming-Ru Wu, Co-Founder, TroGen Therapeutics
Apr 1415:40
Conference pass

Panel Discussion: The Protein Engineer's Toolkit: Trends Shaping Next-Generation Biologics

Protein Engineering
  • Key advances across antibody, scaffold, and format engineering approaches
  • Balancing innovation with developability, manufacturability, and speed to clinic
  • Emerging trends and where the field is heading over the next five years
Horacio Nastri, VP protein science and technology, Incyte
last published: 18/Nov/26 17:29 GMT

Get involved at Festival of Biologics USA 2027

 

 

TO SPONSOR


Nicholas Matthews

Nicholas.Matthews@terrapinn.com

 

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

Ollie.Mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.